Search

Your search keyword '"Sakata, Yuh"' showing total 7 results
Start Over Author "Sakata, Yuh" Topic chemotherapy
7 results on '"Sakata, Yuh"'

1. Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Author

Ito, Ken, Yuki, Satoshi, Nakatsumi, Hiroshi, Kawamoto, Yasuyuki, Harada, Kazuaki, Nakano, Shintaro, Saito, Rika, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Sakamoto, Naoya, and Komatsu, Yoshito

Published
2022
Full Text
View/download PDF

2. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

Author

Watanabe, Toshiaki, Muro, Kei, Ajioka, Yoichi, Hashiguchi, Yojiro, Ito, Yoshinori, Saito, Yutaka, Hamaguchi, Tetsuya, Ishida, Hideyuki, Ishiguro, Megumi, Ishihara, Soichiro, Kanemitsu, Yukihide, Kawano, Hiroshi, Kinugasa, Yusuke, Kokudo, Norihiro, Murofushi, Keiko, Nakajima, Takako, Oka, Shiro, Sakai, Yoshiharu, Tsuji, Akihito, Uehara, Keisuke, Ueno, Hideki, Yamazaki, Kentaro, Yoshida, Masahiro, Yoshino, Takayuki, Boku, Narikazu, Fujimori, Takahiro, Itabashi, Michio, Koinuma, Nobuo, Morita, Takayuki, Nishimura, Genichi, Sakata, Yuh, Shimada, Yasuhiro, Takahashi, Keiichi, Tanaka, Shinji, Tsuruta, Osamu, Yamaguchi, Toshiharu, Yamaguchi, Naohiko, Tanaka, Toshiaki, Kotake, Kenjiro, Sugihara, Kenichi, and Japanese Society for Cancer of the Colon and Rectum

Published
2018
Full Text
View/download PDF

3. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

Author

Watanabe, Toshiaki, Itabashi, Michio, Shimada, Yasuhiro, Tanaka, Shinji, Ito, Yoshinori, Ajioka, Yoichi, Hamaguchi, Tetsuya, Hyodo, Ichinosuke, Igarashi, Masahiro, Ishida, Hideyuki, Ishihara, Soichiro, Ishiguro, Megumi, Kanemitsu, Yukihide, Kokudo, Norihiro, Muro, Kei, Ochiai, Atsushi, Oguchi, Masahiko, Ohkura, Yasuo, Saito, Yutaka, Sakai, Yoshiharu, Ueno, Hideki, Yoshino, Takayuki, Boku, Narikazu, Fujimori, Takahiro, Koinuma, Nobuo, Morita, Takayuki, Nishimura, Genichi, Sakata, Yuh, Takahashi, Keiichi, Tsuruta, Osamu, Yamaguchi, Toshiharu, Yoshida, Masahiro, Yamaguchi, Naohiko, Kotake, Kenjiro, Sugihara, Kenichi, and Japanese Society for Cancer of the Colon and Rectum

Published
2015
Full Text
View/download PDF

4. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

Author

Watanabe, Toshiaki, Itabashi, Michio, Shimada, Yasuhiro, Tanaka, Shinji, Ito, Yoshinori, Ajioka, Yoichi, Hamaguchi, Tetsuya, Hyodo, Ichinosuke, Igarashi, Masahiro, Ishida, Hideyuki, Ishiguro, Megumi, Kanemitsu, Yukihide, Kokudo, Norihiro, Muro, Kei, Ochiai, Atsushi, Oguchi, Masahiko, Ohkura, Yasuo, Saito, Yutaka, Sakai, Yoshiharu, Ueno, Hideki, Yoshino, Takayuki, Fujimori, Takahiro, Koinuma, Nobuo, Morita, Takayuki, Nishimura, Genichi, Sakata, Yuh, Takahashi, Keiichi, Takiuchi, Hiroya, Tsuruta, Osamu, Yamaguchi, Toshiharu, Yoshida, Masahiro, Yamaguchi, Naohiko, Kotake, Kenjiro, Sugihara, Kenichi, and Japanese Society for Cancer of the Colon and Rectum

Published
2012
Full Text
View/download PDF

6. Pilot Study of Combination Chemotherapy Using Irinotecan plus S-1 for Metastatic Pancreatic Cancer.

Author

Shitara, Kohei, Komatsu, Yoshito, Yuki, Satoshi, Munakata, Masaki, Muto, Osamu, Shimaya, Sen, and Sakata, Yuh

Subjects
CLINICAL trials, COMBINATION drug therapy, PANCREATIC cancer, CANCER treatment, STOMACH cancer, COLON cancer
Abstract

Objective: The aim of this study was to evaluate the efficacy and safety of a combination regimen using irinotecan plus S-1 in patients with metastatic pancreatic cancer. Methods: Based on the results of our previous phase I/II study in patients with gastric and colorectal cancer, we initiated a regimen with irinotecan at 100 mg/m2 on days 1 and 15 and S-1 at 80 mg/m2 starting at day 1 for 14 consecutive days, followed by a 14-day rest period. This treatment was repeated every 28 days. Results: From November 2003 to December 2006, a total of 16 patients were enrolled. All patients presented with metastatic disease. Six patients had received prior gemcitabine. The median number of treatment cycles was 4 (range 1–16) and the response rate was 43.7% (95% confidence interval 19.5–68.1). The median time to progression was 4.9 months, and the median survival time was 11.3 months. Grade 3–4 neutropenia developed in 5 of 16 patients and grade 3 diarrhea in 1 patient. Conclusions: The combination of irinotecan and S-1 is feasible and promising for pancreatic cancer. Further evaluation of this combination chemotherapy is required. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

7. Prolongation of Survival and Improvement in Performance Status following Palliative Chemotherapy in Gastrointestinal Cancer Patients with a Poor Performance Status.

Author

Shitara, Kohei, Munakata, Masaki, Kasai, Masaharu, Muto, Osamu, and Sakata, Yuh

Subjects
GASTROINTESTINAL cancer, PALLIATIVE treatment of cancer, CANCER chemotherapy, PROGNOSIS, TUMOR markers
Abstract

Background: The prognosis of advanced gastrointestinal cancer, especially in patients with poor performance status (PS), is generally dismal. Patients with PS 3–4 are almost ineligible for participation in clinical studies. Patients and Methods: From June 2000 to February 2007, 116 patients with poor PS (PS 3 = 73 and PS 4 = 43) were treated with chemotherapy. Retrospective analysis was performed. Results: Of the 107 patients with at least one measurable lesion, a partial response was obtained in 15 patients (14.0%). Of 65 patients with ascites and/or pleural effusion, 12 patients achieved decreased fluid accumulation. A decline in tumor markers was observed in 30 patients. As a result, 38 patients (32.7%) achieved tumor response, a decrease in fluid accumulation or a decline in tumor markers (responders), which resulted in a survival benefit compared to the other 78 patients without effect (6.9 vs. 2.2 months, p < 0.001). PS improvement was seen in 16 patients (13.8%). Conclusions: The results suggest that chemotherapy may be beneficial in gastrointestinal cancer patients with poor PS, as demonstrated by a certain degree of improvement in PS and survival in responders. Further study is required to confirm the benefit of chemotherapy in this patient population. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results